Aristeia Capital L.L.C. Has $2.34 Million Position in LivaNova PLC $LIVN

Aristeia Capital L.L.C. decreased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 26.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 37,985 shares of the company’s stock after selling 13,700 shares during the quarter. Aristeia Capital L.L.C.’s holdings in LivaNova were worth $2,337,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of LIVN. Armistice Capital LLC grew its holdings in LivaNova by 119.4% during the fourth quarter. Armistice Capital LLC now owns 9,325 shares of the company’s stock valued at $574,000 after purchasing an additional 5,075 shares during the period. Schonfeld Strategic Advisors LLC boosted its position in shares of LivaNova by 37.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 192,638 shares of the company’s stock worth $11,853,000 after purchasing an additional 52,071 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of LivaNova by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after buying an additional 496,165 shares during the period. Abel Hall LLC acquired a new position in shares of LivaNova in the 4th quarter valued at $315,000. Finally, Quantedge Capital Pte Ltd bought a new stake in shares of LivaNova in the 4th quarter valued at $486,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.35% of the stock is owned by corporate insiders.

LivaNova Trading Down 1.2%

LIVN opened at $78.50 on Thursday. The stock has a market capitalization of $4.31 billion, a P/E ratio of 40.26 and a beta of 0.88. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $80.96. The firm’s fifty day simple moving average is $70.01 and its 200 day simple moving average is $66.14. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the prior year, the company earned $0.88 EPS. The company’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, research analysts anticipate that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of several research analyst reports. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Stifel Nicolaus set a $80.00 price target on LivaNova in a report on Wednesday, February 25th. Mizuho raised their price target on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Needham & Company LLC lifted their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Robert W. Baird decreased their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.